Art Rastinehad, DO, Receives 2026 Castle Connolly Top Doctor Honor for 12th Time

Art Rastinehad, DO, has been named a 2026 Castle Connolly Top Doctor, marking the 12th year he has received this esteemed designation. Only 7 percent of the nation's licensed physicians are selected annually as Castle Connolly Top Doctors for their specialties in their regions. Dr. Rastinehad serves as professor of urology and radiology, vice chair of urology at Northwell's Lenox Hill Hospital, and Northwell Health System director for prostate cancer. His clinical and research focus includes precision prostate cancer diagnosis, MRI-targeted biopsy, focal therapy, image-guided treatment, interventional urology, and prostate artery embolization for enlarged prostate/BPH.

“Being recognized as a Castle Connolly Top Doctor is meaningful because it reflects the trust patients and peers place in our work,” said Dr. Rastinehad. “My goal is to help men make clear, informed decisions about prostate cancer, enlarged prostate, and urinary symptoms by coordinating the right evaluation and the most appropriate treatment options for each individual patient. Every patient deserves a careful review of his PSA history, MRI findings, biopsy results, prostate size, urinary symptoms, cancer risk, and personal goals before choosing a treatment path. Precision prostate care means matching the right patient to the right diagnosis and the right treatment — not taking a one-size-fits-all approach.”

Dr. Rastinehad's research team has significantly influenced the field of image-guided prostate care, including early validation of MR/US fusion biopsy for prostate cancer detection in the United States. His ongoing work advances prostate cancer diagnosis, focal therapy planning, minimally invasive treatment, and interventional options for men with BPH. Dr. Rastinehad was the first dual fellowship-trained urologic oncologist and interventional radiologist, completing advanced training through the National Institutes of Health, the National Cancer Institute, and Northwell's North Shore University Hospital. This unique background enables him to combine cancer surgery, advanced imaging, and minimally invasive image-guided therapy in one clinical practice.

Key achievements include being part of the first team to publish a series on prostate artery embolization in 2006, early validation of MR/US fusion biopsy for prostate cancer detection, and serving as principal investigator in the development and clinical use of UroNav/Philips MR/US fusion technology for prostate biopsy and focal therapy planning. He is also a founding executive board member of the Focal Therapy Society and has over 20 years of experience in prostate artery embolization and interventional urology. Dr. Rastinehad continues to develop advanced image-guided planning and annotation tools for focal therapy.

Dr. Rastinehad's practice at the urology department at Lenox Hill Hospital provides advanced prostate care for men with elevated PSA, abnormal prostate MRI, localized prostate cancer, enlarged prostate/BPH, urinary symptoms, and complex prostate treatment decisions. Top Doctors are nominated by peer physicians and selected by the physician-led Castle Connolly research team. More information about Castle Connolly Top Doctors can be found at castleconnolly.com.